NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Synergy Pharmaceuticals Inc. (“Synergy” or the “Company”) (NASDAQ: SGYP) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/SGYP-Info-Request-Form-1819. There is no cost or obligation to you.
Synergy issued a press release on September 5, 2017, announcing it had closed on a “non-dilutive” $300 million loan from CRG Partners III L.P., which would be available to Synergy “when needed” and fund the Company’s operations through 2019. On November 14, 2017, Synergy revealed that terms of the loan agreement, omitted from prior statements regarding the loan, prevented it from accessing $200 million of the loan without conducting a dilutive secondary offering or offerings of shares to raise cash and, as such, the Company was conducting a secondary offering of its shares.
To learn more about the investigation of Synergy contact Vincent Wong, Esq. either via email firstname.lastname@example.org, by telephone at 212.425.1140, or visit http://docs.wongesq.com/SGYP-Info-Request-Form-1819.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.